According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the subject of several other research reports. UBS Group upgraded shares of Catalent from a neutral rating to a buy rating and upped their price target for the company from $43.00 to $54.00 in a report on Tuesday, April 16th. First Analysis reiterated an outperform rating and issued a $49.00 price target on shares of Catalent in a report on Tuesday, March 5th. ValuEngine upgraded shares of Catalent from a hold rating to a buy rating in a report on Monday, April 15th. Jefferies Financial Group upgraded shares of Catalent from a hold rating to a buy rating and upped their price target for the company from $50.00 to $62.00 in a report on Friday, June 21st. Finally, Morgan Stanley upped their price target on shares of Catalent from $46.00 to $50.00 and gave the company an overweight rating in a report on Tuesday, April 16th. Nine analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $53.57.
Shares of NYSE CTLT opened at $52.97 on Monday. The firm has a market capitalization of $7.75 billion, a PE ratio of 33.31, a P/E/G ratio of 2.73 and a beta of 1.57. The firm’s 50 day moving average price is $47.56. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.71 and a current ratio of 2.18. Catalent has a 52-week low of $29.23 and a 52-week high of $54.10.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.07. The firm had revenue of $617.50 million during the quarter, compared to analysts’ expectations of $644.88 million. Catalent had a net margin of 6.01% and a return on equity of 16.78%. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.41 earnings per share. On average, analysts forecast that Catalent will post 1.71 EPS for the current year.
In other Catalent news, Director Donald E. Morel, Jr. bought 10,000 shares of Catalent stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average price of $44.44 per share, for a total transaction of $444,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory T. Lucier bought 2,000 shares of Catalent stock in a transaction that occurred on Thursday, May 9th. The shares were acquired at an average price of $45.08 per share, with a total value of $90,160.00. The disclosure for this purchase can be found here. Insiders have purchased 56,500 shares of company stock valued at $2,542,845 in the last 90 days. 1.40% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its position in Catalent by 17.6% during the first quarter. Janus Henderson Group PLC now owns 17,503,223 shares of the company’s stock worth $710,456,000 after acquiring an additional 2,620,352 shares in the last quarter. Norges Bank bought a new stake in Catalent during the fourth quarter worth $47,177,000. Vanguard Group Inc raised its position in Catalent by 9.4% during the third quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock worth $588,763,000 after acquiring an additional 1,110,779 shares in the last quarter. BlackRock Inc. raised its position in Catalent by 7.9% during the first quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock worth $564,971,000 after acquiring an additional 1,023,315 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in Catalent by 39.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,369,230 shares of the company’s stock worth $73,872,000 after acquiring an additional 665,326 shares in the last quarter. Institutional investors and hedge funds own 96.85% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.